ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments · last filed 2023-03-23
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2022-12-31 was $0.00.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2022-09-30 was $0.00.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2022-06-30 was $0.00.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2022-03-31 was $0.00.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2022 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |